Universidad Peruana Cayetano Heredia

Drug-resistance mechanisms and tuberculosis drugs

Mostrar el registro sencillo del ítem

dc.contributor.author Koser, Claudio U.
dc.contributor.author Javid, Babak
dc.contributor.author Liddell, Kathleen
dc.contributor.author Ellington, Matthew J.
dc.contributor.author Feuerriegel, Silke
dc.contributor.author Niemann, Stefan
dc.contributor.author Brown, Nicholas M.
dc.contributor.author Burman, William J.
dc.contributor.author Abubakar, Ibrahim
dc.contributor.author Ismail, Nazir A.
dc.contributor.author Moore, David Alexander James
dc.contributor.author Peacock, Sharon J.
dc.contributor.author Torok, M. Estee
dc.date.accessioned 2019-02-06T14:59:06Z
dc.date.available 2019-02-06T14:59:06Z
dc.date.issued 2015
dc.identifier.uri https://hdl.handle.net/20.500.12866/5535
dc.description.abstract Bedaquiline and delamanid, novel classes of anti-tuberculosis drugs, have been recently approved for the treatment of multidrug-resistant tuberculosis. Antimicrobial resistance invariably follows the introduction of new drugs, and appropriate drug-susceptibility testing assays are needed to detect resistance and tailor treatment regimens that contain new agents. Given that phenotypic drug-susceptibility testing is slow, technically demanding, and, in some cases, unreliable, future assays are likely to be based on rapid molecular techniques. To design such assays, research to unravel the genetic basis of resistance is urgently required (appendix). The question is how to ensure that this research occurs in a timely way, before the emergence and spread of resistance. en_US
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartofseries Lancet
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Humans en_US
dc.subject Antitubercular Agents/therapeutic use en_US
dc.subject Diarylquinolines/therapeutic use en_US
dc.subject Drug Approval en_US
dc.subject Mutation/genetics en_US
dc.subject Nitroimidazoles/therapeutic use en_US
dc.subject Oxazoles/therapeutic use en_US
dc.subject Tuberculosis, Multidrug-Resistant/genetics/prevention & control en_US
dc.title Drug-resistance mechanisms and tuberculosis drugs en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1016/S0140-6736(14)62450-8
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.00
dc.relation.issn 1474-547X


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas